Papers:
What are Juvenile-onset systemic sclerosis providers thoughts, experiences, and reasons for autologous stem cell transplant? Result of a multinational survey – Foeldvari I; Branton S., Li S et al.
November 2024; Journal of Scleroderma and Related Disorders; DOI: 10.1177/23971983241293297
Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance – the result of the International Hamburg Consensus Meeting December 2022 – Foeldvari I, Torok KS, Anton J et al.
December 2023; Expert Review of Clinical Immunology; DOI: 10.1080/1744666X.2023.2298354
Proposed response parameters for 12 months drug trial in Juvenile Systemic Sclerosis. Results of the Hamburg International Consensus Meetings. – Foeldvari I, Torok KS, Klotsche J et al.
September 2023, Arthritis Care & Research 75(12); DOI: 10.1002/acr.25171
How is pulmonary function assessed in patients with juvenile systemic sclerosis? Do we have a good clinical standard?
April 2023; The Journal of Rheumatology 50(9): jrheum.2022-0993; DOI: 10.3899/jrheum.2022-0993
Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis
April 2023; Journal of Scleroderma and Related Disorders 8(10):239719832311647; DOI: 10.1177/23971983231164700
Gender differences in juvenile systemic sclerosis patients: Results from the international juvenile scleroderma inception cohort
December 2022; Journal of Scleroderma and Related Disorders 8(2):239719832211432; DOI: 10.1177/23971983221143244
Differences sustained between diffuse and limited forms of juvenile systemic sclerosis in expanded international cohort.
April 2021; Arthritis Care & Research DOI: 10.1002/acr.24609
Under detection of interstitial lung disease in juvenile systemic sclerosis (jSSc)
November 2020; Arthritis Care and Research DOI: 10.1002/acr.24499
Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort
August 2018; Journal of Scleroderma and Related Disorders 4(2):239719831879049; DOI: 10.1177/2397198318790494
Abstracts:
2024:
Is there a difference in the number of involved organ systems between juvenile diffuse and limited subtype systemic sclerosis patients?
November 2024; ACR Convergence 2024
Improvement across physician and patient reported outcome measures over a 24 months-time period in the juvenile systemic scleroderma inception cohort
November 2024; ACR Convergence 2024
Presence of nailfold capillary changes correlates with more severe organ involvement in juvenile systemic scleroderma. Results of the juvenile scleroderma inception cohort.
November 2024; ACR Convergence 2024
What are the indications for juvenile-onset systemic sclerosis and autologous stem cell transplant. Result of a multinational survey
November 2024; ACR Convergence 2024
Guidance for stem cell therapy for juvenile systemic sclerosis patients
November 2024; ACR Convergence 2024
Is there a difference in the number of involved organ systems between juvenile diffuse and limited subtype systemic sclerosis patients?
September 2024; 31st European Paediatric Rheumatology Congress (PReS 2024)
Improvement across physician and patient reported outcome measures over a 24 months-time period in the juvenile systemic scleroderma inception cohort
September 2024; 31st European Paediatric Rheumatology Congress (PReS 2024)
Presence of nailfold capillary changes correlates with more severe organ involvement in juvenile systemic scleroderma. Results of the juvenile scleroderma inception cohort.
September 2024; 31st European Paediatric Rheumatology Congress (PReS 2024)
What are the indications for juvenile-onset systemic sclerosis and autologous stem cell transplant. Result of a multinational survey
September 2024; 31st European Paediatric Rheumatology Congress (PReS 2024)
Is there a difference in the number of involved organ systems between juvenile diffuse and limited subtype systemic sclerosis patients?
September 2024; 31st European Paediatric Rheumatology Congress (PReS 2024)
Guidance for stem cell therapy for juvenile systemic sclerosis patients
September 2024; 31st European Paediatric Rheumatology Congress (PReS 2024)
POS0770 Differences in clinical presentation between juvenile systemic sclerosis patients with diffuse and limited subtype. Results from the juvenile scleroderma inception cohort.
June 2024; EULAR European Congress of Rheumatology 2024
POS0758 Presence of nailfold capillary changes correlates with more severe organ involvement in juvenile systemic scleroderma. Results of the juvenile scleroderma inception cohort.
June 2024; EULAR European Congress of Rheumatology 2024
2023:
Diffuse juvenile systemic sclerosis patients show distinct organ involvement, antibody pattern and have more severe disease in the largest jssc cohort of the world. Results from the juvenile scleroderma inception cohort
November 2023; ACR Convergence 2023
Over a 36-time period in the juvenile systemic scleroderma inception cohort
November 2023; ACR Convergence 2023
The pattern of medication use significantly changed over 36 months observation period. Result from the juvenile scleroderma inception cohort
November 2023; ACR Convergence 2023
Diffuse juvenile systemic sclerosis patients show distinct organ involvement, antibody pattern and have more severe disease in the largest jssc cohort of the world. Results from the juvenile scleroderma inception cohort
September 2023; 29th European Paediatric Rheumatology Congress (PReS 2023)
Anti-topoisomerase positivity is not associated with baseline organ severity in juvenile systemic sclerosis improvement across organ system, physician and patient reported outcome measures.
September 2023; 29th European Paediatric Rheumatology Congress (PReS 2023)
Over a 36-time period in the juvenile systemic scleroderma inception cohort
September 2023; 29th European Paediatric Rheumatology Congress (PReS 2023)
The pattern of medication use significantly changed over 36 months observation period. Result from the juvenile scleroderma inception cohort
September 2023; 29th European Paediatric Rheumatology Congress (PReS 2023)
Application of criss score, revised criss score and rcid score in patients with diffuse cutaneous juvenile systemic sclerosis.
September 2023; 29th European Paediatric Rheumatology Congress (PReS 2023)
AB1419 Is decreased body mass index -2 z score or less correlating with an organ involvement pattern? Results from the juvenile scleroderma inception cohort
May 2023; EULAR European Congress of Rheumatology 2023
POS0141 Application of criss score, revised criss score and rcid score in patients with juvenile systemic sclerosis
May 2023; EULAR European Congress of Rheumatology 2023
POS0140 Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 24 months observation period in the juvenile systemic scleroderma inception cohort
May 2023; EULAR European Congress of Rheumatology 2023
POS0139 Diffuse juvenile systemic sclerosis patients show distinct organ involvement, antibody pattern and have significantly more severe disease in the largest jssc cohort of the world. Results from the juvenile scleroderma inception cohort
May 2023; EULAR European Congress of Rheumatology 2023
2022:
Patient and Physician Reported Outcomes of Juvenile Systemic Sclerosis Patients Significantly Improve over 12 Months Observation Period in the Juvenile Systemic Scleroderma Inception Cohort
November 2022; ACR Convergence 2022
Juvenile Systemic Sclerosis Treatment Practices in an International Cohort and Comparison to Recent SHARE Consensus Guidelines
November 2022; ACR Convergence 2022
Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the the Juvenile Scleroderma Inception Cohort
November 2022; ACR Convergence 2022
P329. Juvenile systemic sclerosis treatment practices in an international cohort and comparison to recent share consensus guidelines
September 2022; 28th European Paediatric Rheumatology Congress (PReS 2022)
P328. Diffuse juvenile systemic sclerosis patients show distinct organ involvement and have more severe disease in the largest JSSC cohort of the world. Results from the the juvenile scleroderma inception cohort
September 2022; 28th European Paediatric Rheumatology Congress (PReS 2022)
POS1302 Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 12 months observation period in the juvenile systemic scleroderma inception cohort. www.juvenile-scleroderma.com
June 2022; EULAR European Congress of Rheumatology 2022
POS0172 Diffuse juvenile systemic sclerosis patients show distinct organ involvement and have more severe disease in the largest jssc cohort of the world. Results from the juvenile scleroderma inception cohort. Www.juvenile-scleroderma.com
June 2022; EULAR European Congress of Rheumatology 2022
POS1299 Juvenile systemic sclerosis treatment practices in an international cohort and comparison to recent share consensus guidelines
June 2022; EULAR European Congress of Rheumatology 2022
P.123 How is pulmonary function assessed in juvenile systemic scleroderma patient? Do we have a good clinical standard? Results from the juvenile scleroderma inception cohort
March 2022; Conference: 7th Systemic Sclerosis World Congress March 10-12, 2022
P.122 Juvenile systemic sclerosis (jssc) patients with overlap characteristics do not have mild disease. Results from the jssc inception cohort
March 2022; Conference: 7th Systemic Sclerosis World Congress March 10-12, 2022
P.121 Male juvenile systemic sclerosis patients have more severe disease.
Results from the international juvenile scleroderma inception cohort
March 2022; Conference: 7th Systemic Sclerosis World Congress March 10-12, 2022
P.120 Patients with juvenile systemic sclerosis have a distinct pattern of organ involvement. Results from the juvenile systemic sclerosis inception cohort
March 2022; Conference: 7th Systemic Sclerosis World Congress March 10-12, 2022
2021:
Male Juvenile Systemic Sclerosis Patients Have More Severe Disease: Results from the International Juvenile Scleroderma Inception Cohort
November 2021; Conference: ACR Convergence 2021
Patients with Juvenile Systemic Sclerosis Have a Distinct Pattern of Organ Involvement: Results from the Juvenile Systemic Sclerosis Inception Cohort
November 2021; Conference: ACR Convergence 2021
P273 Patients with juvenile systemic sclerosis have a distinct pattern of organ involvement. Results from the juvenile systemic sclerosis inception cohort. www.juvenilescleroderma.com
September 2021; Conference: 27th European Paediatric Rheumatology Congress (PReS 2021)
P271 Male juvenile systemic sclerosis patients have more severe disease: results from the international juvenile scleroderma inception cohort. www.juvenile-scleroderma.com
September 2021; Conference: 27th European Paediatric Rheumatology Congress (PReS 2021)
POS1304 Juvenile systemic sclerosis (jssc) patients with overlap characteristics do not have mild disease. Results from the jssc inception cohort. www.juvenilescleroderma.com
June 2021; Annals of the Rheumatic Diseases; 80(Suppl 1):934.1-934
POS0079 Patients with juvenile systemic sclerosis have a distinct pattern of organ involvement. Results from the juvenile systemic sclerosis inception cohort. www.juvenile-scleroderma.com
June 2021; Annals of the Rheumatic Diseases; 80(Suppl 1):247.2-247
2020:
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests. Results from the Juvenile Scleroderma Inception Cohort
November 2020; Conference: ACR Convergence 2020
Under detection of interstitial lung disease in juvenile systemic sclerosis (jSSc)
November 2020; Arthritis Care and Research DOI: 10.1002/acr.24499
FRI0454 Under detection of interstitial lung disease in juvenile systemic sclerosis (jssc) utilizing pulmonary function tests. Results from the juvenile scleroderma inception cohort
June 2020; Annals of the Rheumatic Diseases 79(Suppl 1):824.1-824
THU0499 Is there a different presentation of juvenile systemic diffuse and limited subset? Data from the juvenile scleroderma inception cohort.
June 2020; Annals of the Rheumatic Diseases 79(Suppl 1):487-488
SAT0500 How the adult criss works in pediatric jssc patients – Results from the juvenile scleroderma inception cohort
June 2020; Annals of the Rheumatic Diseases 79(Suppl 1):1206.2-1206
FRI0466 No disease progression after 36 months follow up in the juvenile systemic scleroderma inception cohort
June 2020; Annals of the Rheumatic Diseases 79(Suppl 1):830.1-831; DOI:
P.346 Is the presentation and severity different of the juvenile diffuse and limited subtype systemic sclerosis? Results of juvenile scleroderma inception cohort
May 2020; Conference: 6th Systemic Sclerosis World Congress July 12-14, 2020
P.344 Under detection of interstitial lung disease in juvenile systemic sclerosis (jssc) utilizing pulmonary function tests. Results from the juvenile scleroderma inception cohort
May 2020; Conference: 6th Systemic Sclerosis World Congress July 12-14, 2020
P.345 How the adult CRISS works in pediatric jssc patients – Results from the juvenile scleroderma inception cohort
May 2020; Conference: 6th Systemic Sclerosis World Congress July 12-14, 2020
CO.26 Validation of disease activity measures in patients with jssc – Results from the jssc inception cohort
May 2020; Conference: 6th Systemic Sclerosis World Congress July 12-14, 2020
2019:
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort
November 2019; 2019 ACR/ARP Annual Meeting
Is the Presentation and Severity Different of the Juvenile Diffuse and Limited Subtype Systemic Sclerosis? Results of Juvenile Scleroderma Inception Cohort
November 2019; 2019 ACR/ARP Annual Meeting
SAT0478 After 24 months observation period the patients related outcomes improve significantly in the juvenile scleroderma inceptions cohort.
www.juvenile-scleroderma.com
June 2019; Annals of the Rheumatic Diseases 78(Suppl 2):1327-1327
AB0967 Is there a difference in presentation of female and male patients with juvenile systemic scleroderma. An update from the juvenile systemic scleroderma inception cohort.
www.juvenile-scleroderma.com
June 2019; Annals of the Rheumatic Diseases 78(Suppl 2):1949-1950.
SAT0479 Update from the juvenile scleroderma inception cohort.
www.juvenile-scleroderma.com
May 2019; Annals of the Rheumatic Diseases 78(Suppl 2):1720
2018:
Update from the Juvenile Scleroderma Inception Cohort
October 2018; Arthritis and Rheumatology 70(59):1557-8
THU0578 Patients and physician related outcomes improve significantly over 12 months follow up in patients with juvenile systemic sclerosis. results from the Juvenile Scleroderma Inception Cohort.
www.juvenile-scleroderma.com
June 2018; Annals of the Rheumatic Diseases 77((Suppl 2)):490
THU0577 Do raynaud phenomenon negative juvenile systemic scleroderma patients have a different pattern of organ involvement as raynaud phenomenon positive patients?
June 2018; Annals of the Rheumatic Diseases 77(Suppl 2):490.1-490
2017:
Are Patients with Overlap Features Different from Patients without? Results from the Juvenile Systemic Scleroderma Cohort
www.juvenile-scleroderma.com
September 2017; Arthritis & Rheumatology 69(suppl 10)
Performance of Juvenile Scleroderma Classification Criteria for Juvenile Systemic Sclerosis. Results from the Jssc Inception Cohort
September 2017, Arthritis & Rheumatology 69(suppl 10)
Male Patients Have a More Severe Course As Female Patients with Diffuse Juvenile Systemic Scleroderma? Results from the Juvenile Scleroderma Inception Cohort
ww.juvenile-scleroderma.com
September 2017, Arthritis & Rheumatology 69(suppl 10):2017
AB0957 Is there a difference in the clinical presentation of juvenile systemic scleroderma patients according the age of onset: results from the juvenile scleroderma inception cohort
www.juvenile-scleroderma.com
Article in Annals of the rheumatic diseases 76(Suppl 2):1389-90 · June 2017
2016:
Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 80 Patients at First Assessment
Article in Arthritis & Rheumatology 68(Suppl 10) · November 2016
Is There a Difference in the Presentation of Diffuse and Limited Subtype in Childhood? Results from the Juvenile Scleroderma Inception Cohort
Article in Arthritis & Rheumatology 68(Suppl 10) · November 2016
Medication Use in the Juvenile Systemic Sclerosis Inception Cohort. Are There Differences in the Diffuse and Limited Subset Patients?
Article in Arthritis & Rheumatology 68(Suppl 10) · November 2016
SAT0257 Update on The Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of The First 74 Patients at First Assessment
Article · June 2016
DOI: 10.1136/annrheumdis-2016-eular.2636
THU0230 Is There A Difference in The Presentation of Male and Female Patients with Juvenile Systemic Sclerosis? Results from The Juvenile Scleroderma Inception Cohort
Article · June 2016
DOI: 10.1136/annrheumdis-2016-eular.2700
2015:
Is There a Difference in the Presentation of Diffuse and Limited Subtype of Juvenile Systemic Sclerosis in Childhood? Results from the Juvenile Scleroderma Inception Cohort
www.juvenile-scleroderma.com
Article in Arthritis & Rheumatology 67(S10) · November 2015
Performance of the Adult Systemic Sclerosis Classification in Juvenile Systemic Sclerosis Patients. Results from the Juvenile Systemic Sclerosis Inception Cohorte
www.juvenile-scleroderma.com
Article in Arthritis & Rheumatology 67(S10) · November 2015
Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 50 Patients at First Assessment.
www.juvenile-scleroderma.com
Article in Arthritis & Rheumatology 67(S10) · November 2015
THU0511 Update on the Juvenile Systemic Sclerosis Inception Cohort.
www.juvenile-scleroderma.com
Article in Annals of the Rheumatic Diseases 74(Suppl2):385 · June 2015
OP0306 Is there a Difference in the Presentation of Diffuse and Limited Subtype of Juvenile Systemic Sclerois in Childhood? Results from the Juvenile Scleroderma Inception Cohorte.
www.juvenile-scleroderma.com
Article in Annals of the Rheumatic Diseases 74(Suppl2):189 · June 2015